Bausch Health and Lannett have settled a decadelong lawsuit regarding claims the drugmakers colluded to inflate generic drug prices, according to court documents filed in the U.S. District Court for the District of Connecticut.
In agreeing to pay nearly $18 million combined, the two drugmakers on Feb. 2 settled allegations of conspiring “to fix prices and allocate markets for many generic drugs” in violation of antitrust laws and consumer protection laws, according to the settlement.
Originally filed in 2016, the lawsuit’s plaintiff list expanded over the years to include 44 states, the District of Columbia, Puerto Rico, the Virgin Islands and the Northern Mariana Islands. The states not part of the lawsuit are Alabama, Arkansas, Hawaii, Louisiana, Missouri and Texas.
Lannett will pay $13.8 million and Bausch will pay $4.1 million, and both will implement internal reforms to ensure compliance with antitrust laws, including annual training of sales and management staff.
The larger, ongoing lawsuit lists dozens of drug manufacturers and senior pharmaceutical executives as defendants.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.